INCRETIN THERAPY ROUNDTABLE: Putting recommendations into practice

Program guide

TABLE OF CONTENTS

Objectives	2
Case study and interactive questions	3
Top 5 clinical tips	11

OBJECTIVES

After attending this program, participants will be able to:

- 1. Summarize relevant updates to the 2013 CDA guideline recommendations for the management of type 2 diabetes.
- 2. Differentiate between DPP-4 inhibitors and GLP-1 receptor agonists.
- 3. Explain how to optimally incorporate DPP-4 inhibitors and GLP-1 receptor agonists into clinical practice for better patient outcomes.

CASE STUDY

MEET WILLIAM





3

................

Initiating treatment

- 1. What should William's target A1C be? [page 2, slide 1]
- 2. Would you initiate a lifestyle intervention alone or lifestyle plus metformin? [page 2, slides 2-4; page 3, slide 5]

Additional notes:

CASE UPDATE



Next steps for William

1. Would you uptitrate metformin or add a second antihyperglycemic agent? [page 3, slides 6 & 7]

2. What are William's second-line treatment options and how do you individualize the treatment choice? [page 3, slide 8; page 4, slide 9]

3. Do you think William could benefit from the early use of an incretin agent as add-on to metformin? [page 4, slide 9]

4. What are the similarities and differences between DPP-4 inhibitors and GLP-1 receptor agonists? [page 4, slides 10-12; page 5, slides 13, 14 & 16; page 6, 17]

5. Using the prescription pads given, how would you prescribe a DPP-4 inhibitor? A GLP-1 receptor agonist?

R _X	PATIENT NAME: ADDRESS:	P _X	PATIENT NAME: ADDRESS:
DIRECTIONS:		DIRECTIONS:	
SIGNATURE :	DATE :	SIGNATURE :	DATE :

R _X	PATIENT NAME: ADDRESS:	$\mathbf{R}_{\mathbf{X}}$	PATIENT NAME: ADDRESS:
DIRECTIONS:		DIRECTIONS:	
SIGNATURE :	DATE :	SIGNATURE :	DATE :
R _X	PATIENT NAME: ADDRESS:	<u>R</u>	PATIENT NAME: ADDRESS:
DIRECTIONS:		DIRECTIONS:	
SIGNATURE :	DATE :	- SIGNATURE :	DATE :

Additional notes:

CASE UPDATE (SCENARIO 1)




Overcoming objections to GLP-1 receptor agonists

1. What are some common patient barriers to initiating GLP-1 receptor agonists and how might you help manage these barriers? [page 6, slides 19 & 20]

2. Do you or your patients have any other major safety concerns with the use of GLP-1 receptor agonists? How do you address these concerns in your practice? [page 7, slides 21 & 22]

CASE UPDATE (SCENARIO 2)



Next steps post DPP-4 inhibitor

1. What are the common adverse events reported with DPP-4 inhibitors? [page 7, slide 23]

2. Are there any cardiovascular safety data on DPP-4 inhibitors or GLP-1 receptor agonists? [page 7, slide 24]

.

3. What are the recommendations for prescribing DPP-4 inhibitors in moderate or severe renal impairment? GLP-1 receptor agonists? [page 8, slide 25]

6 6

0000

.....

4. Do you think William could benefit from being switched to a GLP-1 receptor agonist? Why or why not? [page 8, slide 26]

5. Would you add a third antihyperglycemic agent to William's metformin plus DPP-4 inhibitor, or would you switch the DPP-4 inhibitor to a GLP-1 receptor agonist? Discuss the advantages and disadvantages of your preferred approach. [page 4, slide 9]

Additional notes:

0 0 0 0

6 6 6 6

TOP 5 CLINICAL TIPS

0 0 0

63 63

000

6 6

In the space provided below, record your top 5 take-home clinical tips from this educational program.

1	
2	
3	
4	
5	

Summary of key learnings

- Target A1C \leq 7% is appropriate for *most* patients
- Early, aggressive glycemic control, ideally without weight gain or hypoglycemia is essential to minimizing the risk of diabetes complications

 incretin therapies can help to safely achieve this
- Adding a second antihyperglycemic agent to submaximal metformin is more effective and will have fewer side effects than uptitrating metformin
- Consider key characteristics when selecting a second-line therapy (including A1C effect, and impact on body weight and hypoglycemia risk)
- Incretin therapies can and should be used early in the treatment continuum if target A1C is not being achieved
- GLP-1 receptor agonists, in particular, are more effective than DPP-4 inhibitiors at reducing A1C and body weight, and can help patients (including those near target) reach glycemic goals when added on to or switched from existing antihyperglycemic therapy
- Objections to GLP-1 receptor agonists are readily manageable and can be overcome

INCRETIN THERAPY ROUNDTABLE: Putting recommendations into practice

Resource guide

REFERENCE MATERIAL

.........


0 0


0 0

0

....


.......









.........................





.........................



	Relative A1C lowering	Change in body weight	Overall risk of hypoglycemia	Cost
lpha glucosidase hhibitor (acarbose)	¥	Neutral to ψ	Rare	\$\$
PP-4 inhibitors	$\downarrow \downarrow$	Neutral to ↓	Rare	\$\$\$
LP-1 receptor agonists	↓↓ to ↓↓↓	$\downarrow\downarrow$	Rare	\$\$\$\$
nsulin	$\downarrow \downarrow \downarrow \downarrow$	$\uparrow \uparrow$	Yes	\$-\$\$\$\$
leglitinides	$\downarrow \downarrow$	^	Yes	\$\$
ulfonylureas	$\downarrow \downarrow$	^	Yes	\$
ZDs	$\downarrow \downarrow$	$\uparrow \uparrow$	Rare	\$\$
/eight loss agent (orlistat)	+	\downarrow	None	\$\$\$
GLT2 inhibitors are now av	vailable, but are	currently not i	n the guidelines.	


0 0 0

0000


0


0 0 0


0 0




.......................











6 6

0 0







....


00 00

0 0












6 6 6

63

.







0000

0 0 0 0 0

8 6

63

....

0

